Abstract
Introduction: The Oncotype Dx recurrence score (RS) predicts chemotherapy benefit based on the 21-gene breast cancer assay. We set out to evaluate the implementation of the Oncotype Dx score on MDT decision making and to investigate its' impact on our service.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
